Targeting the estrogen receptor with SERMs is an effective treatment in early and metastasized breast cancer, although the problem of SERM resistance is an unresolved issue.18 The relevance of COX-2 expression and targeting by COX-2 inhibitors like celecoxib is an exciting experimental and clinical research area. This evidence concerns the gene PTGS2 and breast cancer.